Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial
Flippot, R., Dalban, C., Laguerre, B., Borchiellini, D., Gravis, G., Negrier, S., Chevreau, C.M., Joly, F., Geoffrois, L., Ladoire, S., Mahammedi, H., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Impact of Early Consumption of High-Fat Diet on the Mesolimbic Dopaminergic System
Naneix, F, Tantot, F, Glangetas, C, Kaufling, J, Janthakhin, Y, Boitard, C, De Smedt-Peyrusse, V, Pape, J R, Vancassel, S, Trifilieff, P, Georges, F, Coutureau, E, Ferreira, G
Published in eNeuro (01.05.2017)
Published in eNeuro (01.05.2017)
Get full text
Journal Article
687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
Carril Ajuria, L., Naigeon, M., Dalban, C., Desnoyer, A., Rioux-Leclercq, N., Sautès-Fridman, C., Meylan, M., Vano, Y., Beuselinck, B., Chouaib, S., de Oliveira, C., Tantot, F., Escudier, B., Albiges, L., Chaput, N.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
Colomba, E., Carril Ajuria, L., Dalban, C., Derosa, L., Alves Costa Silva, C., Rassy, E., Negrier, S., Chevreau, C.M., Gravis Mescam, G., Oudard, S., Laguerre, B., Barthelemy, P., Gross Goupil, M., Geoffrois, L., Thiery-Vuillemin, A., Joly Lobbedez, F., Ladoire, S., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
972PFresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome
Desnoyer, A, Larive, A, Drubay, D, Lanoy, E, Vano, Y, Rioux-Leclercq, N, Chouaib, S, Beuselinck, B, Tantot, F, Escudier, B, Chaput, N, Albiges, L
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
972P - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome
Desnoyer, A., Larive, A., Drubay, D., Lanoy, E., Vano, Y., Rioux-Leclercq, N., Chouaib, S., Beuselinck, B., Tantot, F., Escudier, B., Chaput, N., Albiges, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome
Desnoyer, A., Larive, A., Drubay, D., Lanoy, E., Vano, Y., Rioux-Leclercq, N., Chouaib, S., Beuselinck, B., Tantot, F., Escudier, B., Chaput, N., Albiges, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial
Courcier, J., Dalban, C., Laguerre, B., Ladoire, S., Barthélémy, P., Oudard, S., Joly, F., Gravis Mescam, G., Chevreau, C.M., Geoffrois, L., Deluche, E., Rolland, F., Topart, D., Culine, S., Négrier, S., Mahammedi, H., Tantot, F., Escudier, B., Flippot, R., Albiges, L.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
646TiP A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer
Blanchard, P., Foulon, S., Artignan, X., Carles, J., Ronchin, P., Gizzi, M., Villa Freixa, S., Valdagni, R., Sargos, P., Marques Da Costa, L.A., Duberge, T., Guillot, A., Latorzeff, I., Gallardo, E., Sáez, M.I., Abadie-Lacourtoisie, S., Bennamoun, M., Hasbini, A., Tantot, F., Fizazi, K.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
Kinget, L., Roussel, E., Lambrechts, D., Boeckx, B., Verbiest, A.T.L., Zucman-Rossi, J., Couchy, G., Dalban, C., Meylan, M., Chabaud, S., Vano, Y., Sautès-Fridman, C., Fridman, W-H., Baldewijns, M., Albersen, M., Rioux-Leclercq, N., Tantot, F., Chaput, N., Beuselinck, B., Albiges, L.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
Alves Costa Silva, C., Derosa, L., Dalban, C., Colomba, E., Negrier, S., Chevreau, C.M., Gravis, G., Oudard, S.M., Laguerre, B., Barthelemy, P., Borchiellini, D., Gross-Goupil, M., Geoffrois, L., Rolland, F., Thiery-Vuillemin, A., Joly, F., Ladoire, S., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study
Derosa, L., Alves Costa Silva, C., Dalban, C., Colomba, E., Negrier, S., Chevreau, C.M., Gravis, G., Oudard, S.M., Laguerre, B., Barthelemy, P., Borchiellini, D., Gross-Goupil, M., Geoffrois, L., Rolland, F., Thiery-Vuillemin, A., Joly, F., Ladoire, S., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
Kinget, L., Roussel, E., Lambrechts, D., Boeckx, B., Verbiest, A. T. L., Zucman-Rossi, Jessica, Couchy, G., Dalban, C., Meylan, M., Chabaud, S., Vano, Y., Sautes-Fridman, C., Fridman, W-H., Baldewijns, M., Albersen, M., Rioux-Leclercq, N., Tantot, F., Chaput, N., Beuselinck, B., Albiges, L.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
Meylan, M., Beuselinck, B., Dalban, C., Vano, Y., Rioux Leclercq, N., Sautès-Fridman, C., Roussel, E., Verbiest, A., Chaput, N., Terry, S., Chevreau, C., Gross-Goupil, M., Fléchon, A., Laguerre, B., Chabaud, S., Tantot, F., Lambrechts, D., Escudier, B., Fridman, W-H., Albiges, L.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
Meylan, M., Beuselinck, B, Dalban, C., Vano, Y., Leclercq, N. Rioux, Sautès-Fridman, C., Roussel, E., Verbiest, A, Chaput, N., Terry, S., Chevreau, C., Gross-Goupil, M., Flechon, A, Laguerre, B., Chabaud, S., Tantot, F., Lambrechts, D., Escudier, B., Fridman, W.-H., Albiges, L.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
868PDBrain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial
Flippot, R, Dalban, C, Laguerre, B, Borchiellini, D, Gravis, G, Negrier, S, Chevreau, C M, Joly, F, Geoffrois, L, Ladoire, S, Mahammedi, H, Tantot, F, Escudier, B, Albiges, L
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma
Lefort, F., Dalban, C., Gross-Goupil, M., Laguerre, B., Barthelemy, P., Sarradin, V., Chanez, B., Negrier, S., Geoffrois, L., Gillon, P., De Vries, M., Ladoire, S., Bolognini, C., Laramas, M., Priou, F., Oudard, S., Chabot, S., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
909PDNIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)
Vano, Y, Rioux-Leclercq, N, Dalban, C, Sautès-Fridman, C, Bougoüin, A, Chaput, N, Chouaib, S, Beuselinck, B, Chevreau, C M, Gross-Goupil, M, Negrier, S, Laguerre, B, Borchiellini, D, Colina-Moreno, I, Fridman, W H, Chabaud, S, Tantot, F, Barros Monteiro, J, Escudier, B, Albiges, L
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
966PImpact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma
Lefort, F, Dalban, C, Gross-Goupil, M, Laguerre, B, Barthelemy, P, Sarradin, V, Chanez, B, Negrier, S, Geoffrois, L, Gillon, P, De Vries, M, Ladoire, S, Bolognini, C, Laramas, M, Priou, F, Oudard, S, Chabot, S, Tantot, F, Escudier, B, Albiges, L
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
966P - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma
Lefort, F., Dalban, C., Gross-Goupil, M., Laguerre, B., Barthelemy, P., Sarradin, V., Chanez, B., Negrier, S., Geoffrois, L., Gillon, P., De Vries, M., Ladoire, S., Bolognini, C., Laramas, M., Priou, F., Oudard, S., Chabot, S., Tantot, F., Escudier, B., Albiges, L.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article